214 related articles for article (PubMed ID: 24797666)
1. Effect of currently approved carriers and adjuvants on the pre-clinical efficacy of a conjugate vaccine against oxycodone in mice and rats.
Pravetoni M; Vervacke JS; Distefano MD; Tucker AM; Laudenbach M; Pentel PR
PLoS One; 2014; 9(5):e96547. PubMed ID: 24797666
[TBL] [Abstract][Full Text] [Related]
2. Reduced antinociception of opioids in rats and mice by vaccination with immunogens containing oxycodone and hydrocodone haptens.
Pravetoni M; Le Naour M; Tucker AM; Harmon TM; Hawley TM; Portoghese PS; Pentel PR
J Med Chem; 2013 Feb; 56(3):915-23. PubMed ID: 23249238
[TBL] [Abstract][Full Text] [Related]
3. Alum adjuvant is more effective than MF59 at prompting early germinal center formation in response to peptide-protein conjugates and enhancing efficacy of a vaccine against opioid use disorders.
Robinson C; Baehr C; Schmiel SE; Accetturo C; Mueller DL; Pravetoni M
Hum Vaccin Immunother; 2019; 15(4):909-917. PubMed ID: 30625019
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Efficacy and Characterization of Candidate Vaccines for Treatment of Opioid Use Disorders Using Clinically Viable Carrier Proteins.
Baruffaldi F; Kelcher AH; Laudenbach M; Gradinati V; Limkar A; Roslawski M; Birnbaum A; Lees A; Hassler C; Runyon S; Pravetoni M
Mol Pharm; 2018 Nov; 15(11):4947-4962. PubMed ID: 30240216
[TBL] [Abstract][Full Text] [Related]
5. The frequency of naive and early-activated hapten-specific B cell subsets dictates the efficacy of a therapeutic vaccine against prescription opioid abuse.
Laudenbach M; Baruffaldi F; Vervacke JS; Distefano MD; Titcombe PJ; Mueller DL; Tubo NJ; Griffith TS; Pravetoni M
J Immunol; 2015 Jun; 194(12):5926-36. PubMed ID: 25972483
[TBL] [Abstract][Full Text] [Related]
6. Hapten-specific naïve B cells are biomarkers of vaccine efficacy against drugs of abuse.
Taylor JJ; Laudenbach M; Tucker AM; Jenkins MK; Pravetoni M
J Immunol Methods; 2014 Mar; 405():74-86. PubMed ID: 24462800
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, but not antibody titer or affinity, of a heroin hapten conjugate vaccine correlates with increasing hapten densities on tetanus toxoid, but not on CRM197 carriers.
Jalah R; Torres OB; Mayorov AV; Li F; Antoline JF; Jacobson AE; Rice KC; Deschamps JR; Beck Z; Alving CR; Matyas GR
Bioconjug Chem; 2015 Jun; 26(6):1041-53. PubMed ID: 25970207
[TBL] [Abstract][Full Text] [Related]
8. Effects of an oxycodone conjugate vaccine on oxycodone self-administration and oxycodone-induced brain gene expression in rats.
Pravetoni M; Pentel PR; Potter DN; Chartoff EH; Tally L; LeSage MG
PLoS One; 2014; 9(7):e101807. PubMed ID: 25025380
[TBL] [Abstract][Full Text] [Related]
9. Formulation and Characterization of Conjugate Vaccines to Reduce Opioid Use Disorders Suitable for Pharmaceutical Manufacturing and Clinical Evaluation.
Baruffaldi F; Raleigh MD; King SJ; Roslawski MJ; Birnbaum AK; Hassler C; Carroll FI; Runyon SP; Winston S; Pentel PR; Pravetoni M
Mol Pharm; 2019 Jun; 16(6):2364-2375. PubMed ID: 31018096
[TBL] [Abstract][Full Text] [Related]
10. Co-administration of morphine and oxycodone vaccines reduces the distribution of 6-monoacetylmorphine and oxycodone to brain in rats.
Pravetoni M; Raleigh MD; Le Naour M; Tucker AM; Harmon TM; Jones JM; Birnbaum AK; Portoghese PS; Pentel PR
Vaccine; 2012 Jun; 30(31):4617-24. PubMed ID: 22583811
[TBL] [Abstract][Full Text] [Related]
11. Liposomes containing monophosphoryl lipid A: a potent adjuvant system for inducing antibodies to heroin hapten analogs.
Matyas GR; Mayorov AV; Rice KC; Jacobson AE; Cheng K; Iyer MR; Li F; Beck Z; Janda KD; Alving CR
Vaccine; 2013 Jun; 31(26):2804-10. PubMed ID: 23624097
[TBL] [Abstract][Full Text] [Related]
12. An oxycodone conjugate vaccine elicits drug-specific antibodies that reduce oxycodone distribution to brain and hot-plate analgesia.
Pravetoni M; Le Naour M; Harmon TM; Tucker AM; Portoghese PS; Pentel PR
J Pharmacol Exp Ther; 2012 Apr; 341(1):225-32. PubMed ID: 22262924
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of an oxycodone vaccine: Addressing some of the unique considerations posed by opioid abuse.
Raleigh MD; Peterson SJ; Laudenbach M; Baruffaldi F; Carroll FI; Comer SD; Navarro HA; Langston TL; Runyon SP; Winston S; Pravetoni M; Pentel PR
PLoS One; 2017; 12(12):e0184876. PubMed ID: 29194445
[TBL] [Abstract][Full Text] [Related]
14. Opioid Dose- and Route-Dependent Efficacy of Oxycodone and Heroin Vaccines in Rats.
Raleigh MD; Laudenbach M; Baruffaldi F; Peterson SJ; Roslawski MJ; Birnbaum AK; Carroll FI; Runyon SP; Winston S; Pentel PR; Pravetoni M
J Pharmacol Exp Ther; 2018 May; 365(2):346-353. PubMed ID: 29535156
[TBL] [Abstract][Full Text] [Related]
15. Combining a Candidate Vaccine for Opioid Use Disorders with Extended-Release Naltrexone Increases Protection against Oxycodone-Induced Behavioral Effects and Toxicity.
Raleigh MD; Accetturo C; Pravetoni M
J Pharmacol Exp Ther; 2020 Sep; 374(3):392-403. PubMed ID: 32586850
[TBL] [Abstract][Full Text] [Related]
16. The frequency of early-activated hapten-specific B cell subsets predicts the efficacy of vaccines for nicotine dependence.
Laudenbach M; Tucker AM; Runyon SP; Carroll FI; Pravetoni M
Vaccine; 2015 Nov; 33(46):6332-9. PubMed ID: 26409811
[TBL] [Abstract][Full Text] [Related]
17. Self-adjuvanting glycopeptide conjugate vaccine against disseminated candidiasis.
Xin H; Cartmell J; Bailey JJ; Dziadek S; Bundle DR; Cutler JE
PLoS One; 2012; 7(4):e35106. PubMed ID: 22563378
[TBL] [Abstract][Full Text] [Related]
18. Prophylactic vaccination protects against the development of oxycodone self-administration.
Nguyen JD; Hwang CS; Grant Y; Janda KD; Taffe MA
Neuropharmacology; 2018 Aug; 138():292-303. PubMed ID: 29936242
[TBL] [Abstract][Full Text] [Related]
19. A Fentanyl Vaccine Alters Fentanyl Distribution and Protects against Fentanyl-Induced Effects in Mice and Rats.
Raleigh MD; Baruffaldi F; Peterson SJ; Le Naour M; Harmon TM; Vigliaturo JR; Pentel PR; Pravetoni M
J Pharmacol Exp Ther; 2019 Feb; 368(2):282-291. PubMed ID: 30409833
[TBL] [Abstract][Full Text] [Related]
20. Pre-clinical safety and toxicology profile of a candidate vaccine to treat oxycodone use disorder.
Hamid FA; Marker CL; Raleigh MD; Khaimraj A; Winston S; Pentel PR; Pravetoni M
Vaccine; 2022 May; 40(23):3244-3252. PubMed ID: 35469698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
